Fidelity Management & Research Company Leads Financing; Nexus Neurotech Ventures and Ally Bridge Group Co-Lead Robust Investor Syndicate. FOR IMMEDIATE RELEASE: HAIFA, ISRAEL AND MIAMI, FL—Insightec, a global healthcare company…
– Proceeds will support clinical development of lead pipeline candidates: ENV-101 for fibrotic lung diseases including idiopathic pulmonary fibrosis, and ENV-501, a next-generation HER3-targeted antibody-drug conjugate, for solid tumors –…
NEW YORK—(BUSINESS WIRE)—Ally Bridge Group (“ABG”), a leading global healthcare investment firm focused on high-impact life science innovation, today announced several key promotions within its investment team and a new…
– Proceeds to support development of ProfoundBio’s differentiated clinical-stage ADC pipeline, including the planned pivotal trial of rinatabart sesutecan (Rina-S) – Financing led by Ally Bridge Group, bolstered by contributions…
The Company continues to deliver on its mission of bringing the benefits of Minimal Access Surgery (MAS) to more patients globally. The Versius® Surgical Robotic System has now been used…
LightForce Orthodontics will expand its manufacturing capabilities to advance production and further its custom orthodontic treatments using AI and 3D printing. BURLINGTON, MA — August 2, 2023 — LightForce Orthodontics,…
Additional financing strengthens Ceribell’s shareholder base and provides capital to support commercial expansion and further development of the company’s first-of-its kind Ceribell Rapid Response EEG System SUNNYVALE, Calif., September 21,…
Ally Bridge Group joins existing syndicate of KCK MedTech, Questa Capital and OrbiMed. Sunnyvale, CA – June 16, 2022 – Aerin Medical Inc., a company dedicated to providing Ear, Nose…
New York, NY—J. Tomilson Hill, Chair, and Wendy Fisher, President, Solomon R. Guggenheim Foundation, today announced that Frank Yu has been elected to the Board of Trustees. In a joint…
Investors say industry’s fundamentals remain strong. By Brian Gormley (WWW.WSJ.COM)–Initial public offerings by biotechnology companies are slowing after two record-setting years as the poor performance of some recent IPOs combined with economic and geopolitical uncertain-ties have cooled interest…
